Navigation Links
Progress toward artificial photosynthesis?

Plants can do it: they simply grab carbon dioxide out of the air and covert it into biomass. In this process, known as photosynthesis, the plants use light as their energy source. Chemists would also like to be able to use CO2 as a carbon source for their synthetic reactions, but it doesn’t work just like that. A team headed by Markus Antonietti at the Max Planck Institute for Colloids and Interfaces has now taken an important step toward this goal. As described in the journal Angewandte Chemie, they have successfully activated CO 2 for use in a chemical reaction by using a special new type of metal-free catalyst: graphitic carbon nitride.

"Chemical activation of carbon dioxide, meaning its cleavage in a chemical reaction," explain chemists Goettmann, Thomas and Antonietti, " is one of the biggest challenges in synthetic chemistry." The bonds in this molecule are very stable, so a lot of energy is needed to split them. To date, only a few special metal catalysts are known to be capable of breaking the C–O bonds in CO2.

In contrast to most previous approaches, Antonietti’s team worked with metal-free catalysts, turning toward plants for inspiration. Photosynthesis in modern green plants involves an important intermediate step: the bonding of CO2 to nitrogen atoms to form carbamates. The German researchers thus also experimented with nitrogen-rich catalysts with structures that allow them to form carbamates. Their new class of catalysts is made of flat, graphite-like layers. The individual layers consist of ring systems involving carbon and nitrogen atoms. This porous material, called graphitic carbon nitride, is very heat-stable and, although it enters into many chemical interactions, it is so stable that it nearly always re-forms—an ideal catalyst. It can even be used to activate carbon dioxide. It was thus possible to oxidize benzene (an aromatic six-membered carbon ring) to phenol (which has an additional OH group). The by-product of the reactio
'"/>

Source:John Wiley & Sons, Inc.


Page: 1 2

Related biology news :

1. Bevacizumab Combined With Chemotherapy Improves Progression-Free Survival for Patients With Advanced Breast Cancer
2. AIDS Public Awareness Campaign Expands Following Report Of Rapidly Progressive HIV
3. Progress on HIV/AIDS significant but insufficient
4. Progress being made in exploring potential use of stem cells to treat heart disease
5. Progress made in HIV vaccine development
6. Unchecked DNA replication drives earliest steps toward cancer
7. Virologists make major step towards understanding the process of HIV infection
8. Moffitt-USF head toward first human trials of anti-cancer drug that targets protein AKT
9. Cats indifference towards sugar explained
10. A step toward the $1,000 personal genome using readily available lab equipment
11. A new step towards an AIDS vaccine

Post Your Comments:
(Date:11/9/2009)...9, 2009 / b3c newswire / - Today, TNO, a Dutch ...an American organization for contract research and...ned a letter of intent with regard to TNOs dynamic...r of intent proposes a collaboration in which Seve...lization in North America. The TIM systems will be...
(Date:11/9/2009)...stry leaders from around the world will gather in ...lecular Targets and Cancer Therapeutics Internatio...information on important cancer therapies in devel...reat it effectively we need a greater understandin...r level," said Lewis Cantley, Ph.D., director of t...
(Date:11/8/2009)...hers at Purdue University have discovered a new ap...l cord injuries using nano-spheres that could be i..., The synthetic "copolymer micelles" are drug-de... roughly 100 times smaller than the diameter of a ... how to deliver drugs for cancer treatment and oth...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 1InVitria Reports Successful Cell Culture Performance of Zap CHO a Defined and Cost Effective CHO Cell Culture Media Supplement 60242 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 1NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 2NeuroVasx Announces First Case of cPAX Aneurysm Treatment System in Spain 60238 3Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 1Health Partners to Offer Health Insurance Through the Childrens Health Insurance Program 60234 2
... When Yadong Wang, a chemist by training, first ve...idn,t know that his peers would have considered hi...cuits use electrical signals often conducted by ne...te between the brain and the rest of the body, he ...ed to repair a broken circuit. The neurotransmitte...
... University of Manchester researchers are recruiti...?commonly known as sciatica ?in the first ever stu...their condition. , Dr Christopher McCarthy and his...n Science need 30 volunteers aged 22-55 who have h...nt and have not had previous spinal surgery. , ...
... Using the latest in high tech tools, researchers ...edictive of chronic lung rejection up to 20 months...patients have the highest mortality rate of organ ...nvestigator and pulmonologist Chris Wendt. Current...splants will fail, and when signs of chronic rejec...
Other Biology News:Dopamine used to prompt nerve tissue to regrow 2Proteins may predict lung transplant rejection 2Proteins may predict lung transplant rejection 3
(Date:11/6/2009)...Newswire-FirstCall/ -- Helix BioPharma Corp. (TSX,...that John Docherty, president and chief operating ...h annual Investor Summit on November 10, 2009 at 4... Docherty will provide an overview of the Company,... Topical Interferon Alpha-2b. The slide show port...
(Date:11/6/2009)...PRNewswire-FirstCall/ -- ,, 3Q09 Corporate H...TM) E.U. Marketing Authorization to Astellas Pharm...rcial readiness activities Expanded management te...; and Director, Commercial Operations Appointed B...Committee chairman , Upcoming 2009 Mileston...
(Date:11/6/2009)...Newswire/ -- Intarcia Therapeutics, Inc. delivered...74; continuous delivery of exenatide) program for ...al Diabetes Technology Meeting in San Francisco, C...nh/20050301/SFTU126LOGO ) ,, Continuous Subcu...Plasma Glucose, HbA1c and Reduces Weight in a 28-d...
(Date:11/5/2009)...PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GN... third quarter ended September 30, 2009. GenVec re...) for the three months ended September 30, 2009 co...are) in the comparable quarter of 2008. For the ni...oss was $14.1 million ($0.15 per share), compared ...
Breaking Biology Technology:Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 2Helix BioPharma to Present at Merriman Curhan Ford's Investor Summit 2009 on November 10th 3NeurogesX Reports Third Quarter 2009 Results 2NeurogesX Reports Third Quarter 2009 Results 3NeurogesX Reports Third Quarter 2009 Results 4NeurogesX Reports Third Quarter 2009 Results 5NeurogesX Reports Third Quarter 2009 Results 6NeurogesX Reports Third Quarter 2009 Results 7NeurogesX Reports Third Quarter 2009 Results 8NeurogesX Reports Third Quarter 2009 Results 9NeurogesX Reports Third Quarter 2009 Results 10Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 2Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 3Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 4Intarcia Therapeutics, Inc. Presents Positive Results from Two Studies of ITCA 650 for the Treatment of Type 2 Diabetes at the Ninth Annual Diabetes Technology Meeting 5GenVec Reports Third Quarter 2009 Financial Results 2GenVec Reports Third Quarter 2009 Financial Results 3GenVec Reports Third Quarter 2009 Financial Results 4GenVec Reports Third Quarter 2009 Financial Results 5GenVec Reports Third Quarter 2009 Financial Results 6
...RDAM, The Netherlands, February 18 ,Amsterdam Mole...e field of,human gene therapy, announced today tha...ll year 2008 on Tuesday, February 24, 2009 at 7:00...results, the Company will,conduct a conference cal... for the Netherlands is 0800-949-4166 (toll free)....
...b., Feb. 18 Transgenomic Inc. (OTC Bulletin Board...hat: Transgenomic Inc. Fourth Quarter 2008 Ear...en: Wednesday, February 25, 2009 @ 5:00 p.m. E...vents.asp?id=6 , How: Live over the Intern... address above., , , To access the call via te...
...ES, Feb. 18 The Board of Directors wishes to conf...y 4, 2009 it resolved to file a Form 15 with effec...t require the approval of stockholders but in the ...olders informed the Board is making this Release. ...ompany from its United States Securities and Excha...
Other Biology Technology:AMT to Release Full Year 2008 Results on February 24, 2009 2Webcast Alert: Transgenomic Inc. Announces Fourth Quarter 2008 Earnings Release Conference Call Webcast 2EESTECH Inc - Release From SEC Filing 2EESTECH Inc - Release From SEC Filing 3EESTECH Inc - Release From SEC Filing 4
SILVER SEQUENCE Staining Reagents from Promega
Sheep Anti-Decorin Polyclonal Antibody, Unconjugated from Abcam
Mouse Complement from Equitech-Bio
...S-4P, all Programmable and Digital Orbital Shaker.... been redesigned to make every day use even easier...memory for up to 4 different programs. Its easy re...am. Furthermore, the VSOS-4P has a pulse operation...
Biology Products: